论文部分内容阅读
监测对治疗用药的服从性一直受到方法学的限制。由于苯巴比妥的药动学在不同的人之间以及同一个体内的变化很小,而且半衰期长,就诊以前服1～2剂不能达到和治疗2周以上相同的血浆浓度。这便使医生们可以通过其血浆浓度的测定来推断病人所述的服药情况是否属实。苯巴比妥特别适合作为监测服从用药的药理标志。本文作者用苯巴比妥标记的土霉素治疗非淋菌性尿道炎(NGU)患者,并对用药的服从性进行了评价。62名诊断为NGU 的患者均为男性,18～39岁。每例患者共给予84片药,每片含土霉素250mg、苯巴比妥2mg,每日4次,每次1片,要求2周后复诊,复诊前不要停药。复诊时询问病人是否遵照医嘱服药,并采血、尿标本测定土霉素和血苯巴比妥浓度,根据患者
Monitoring compliance with therapeutic agents has been limited by methodological considerations. Since the pharmacokinetics of phenobarbital varies little among patients and within the same individual, and has a long half-life, one or two doses of phenobarbital failed to achieve the same plasma concentrations as those treated for more than two weeks. This allows physicians to conclude from their plasma concentration that the patient’s medication is correct. Phenobarbital is particularly suitable as a pharmacological marker for monitoring compliance. The authors used phenobarbital-labeled oxytetracycline to treat patients with non-gonococcal urethritis (NGU) and evaluated their adherence. 62 patients diagnosed with NGU were male, 18 to 39 years old. Each patient was given a total of 84 drugs, each containing oxytetracycline 250mg, phenobarbital 2mg, 4 times a day, each 1, requiring 2 weeks after the referral, do not stop before referral. Referral patients asked whether the patient is prescribed medication, and blood, urine specimens measured oxytetracycline and blood concentration of phenobarbital, according to the patient